Stock DVYSR DEVYSER DIAGNOSTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Devyser Diagnostics AB

Equities

DVYSR

SE0016588867

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:52 2024-05-03 EDT 		5-day change 1st Jan Change
100 SEK +0.60% Intraday chart for Devyser Diagnostics AB -2.91% +27.23%
04-25 Devyser Receives IVDR Approval for Post-Transplant Monitoring Software CI
04-23 Devyser Diagnostics AB Enters into Co-Marketing Agreement with Hamilton Bonaduz AG CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
DEVYSER DIAGNOSTICS AB Stock Devyser Diagnostics AB
+27.23% 148M -
MODERNA, INC. Stock Moderna, Inc.
+25.69% 48.09B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.43B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 24.89B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.01B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.09B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 11.88B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.8B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DVYSR Stock
  4. Ratings Devyser Diagnostics AB